InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,447.87
(
-0.31%
)
US TECH 100
19,026.80
(
0.36%
)
Dow Jones
39,411.21
(
0.00%
)
Brent Oil
84.63
(
-0.76%
)
Bitcoin
61,083.57
(
1.36%
)
Post# of 10489
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

MDMSCF

Send PM Follow Ignore
Followers 0
Posts 37
Boards Moderated 0
Alias Born 10/16/2013

MDMSCF

Re: cdaniel394 post# 7528

Thursday, 03/03/2016 7:17:20 AM

Thursday, March 03, 2016 7:17:20 AM

Post# of 10489
By my calculations, NeuVax is demonstrating a recurrence rate of less than or equal to 7% and an improvement in DFS of approximately 70%.

This is astonishing to me and I think we will see GALE trading in the not so distant future at a Market Cap of at least 5X expected peak annual sales (> 12.5B).

Biden asked for a moonshot for cancer. Well, the NeuVax shuttle has landed. We are just waiting on the FDA to open the door!

The big questions for me is, how often does the biostatistician assigned to the NeuVax IDMC review the recurrence rates? How quickly does the IDMC meet after crossing 70 events? How is the company notified and what time frame do they have to report the event?

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up